Advertisement

Topics

Athersys and Healios Announce Binding Letter of Intent to Expand MultiStem Collaboration

11:41 EDT 13 Mar 2018 | Topix

Athersys, Inc. and HEALIOS K.K. announced today their intent to significantly expand their existing development and commercialization collaboration. As part of this expansion, Healios is making an approximate $21 million equity investment at $1.76 per share, will deposit $10 million into escrow, and has entered into a letter of intent with Athersys to expand Healios' license to develop MultiStemA products for indications to include acute respiratory distress syndrome , trauma in Japan and the use of MultiStem products in conjunction with organ bud technology and certain ophthalmological indications globally.

Original Article: Athersys and Healios Announce Binding Letter of Intent to Expand MultiStem Collaboration

NEXT ARTICLE

More From BioPortfolio on "Athersys and Healios Announce Binding Letter of Intent to Expand MultiStem Collaboration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...